Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial

Area of Science:

• Hematology
• Transfusion Medicine
• Infectious Disease Prevention

Background:

• Pathogen inactivation of platelet concentrates aims to reduce blood-borne infections.
• The impact of pathogen inactivation on platelet function and hemostatic efficacy remains unclear.
• Patients with hematologic malignancies and thrombocytopenia are at high risk for bleeding complications.

Purpose of the Study:

• To compare the efficacy of pathogen-inactivated platelets (using riboflavin and UV B illumination) versus standard platelets in preventing bleeding.
• To assess the noninferiority of pathogen-inactivated platelets in patients undergoing transfusion therapy.

Main Methods:

• A randomized noninferiority trial comparing pathogen-inactivated platelets (intervention) with standard plasma-stored platelets (control).
• Primary outcome: proportion of transfusion-treatment periods with grade 2 or higher bleeding (WHO criteria).
• Intention-to-treat and per-protocol analyses were conducted.

Main Results:

• In the intention-to-treat analysis, noninferiority was met with a 3% absolute difference in grade 2 or higher bleeding (51% control vs. 54% intervention).
• The per-protocol analysis showed an 8% difference (44% control vs. 52% intervention), not meeting noninferiority criteria.
• Transfusion increment parameters were approximately 50% lower in the intervention arm; no difference in HLA alloantibody development.

Conclusions:

• Pathogen-inactivated platelets met noninferiority criteria in the intention-to-treat analysis for preventing bleeding in hematologic malignancy patients.
• The per-protocol analysis did not demonstrate noninferiority, suggesting potential concerns regarding efficacy.
• Lower transfusion increments indicate reduced efficacy of pathogen-inactivated platelets, warranting further investigation.